Opportunity Information: Apply for RFA CA 16 002
Apply for RFA CA 16 002
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394,.
- This funding opportunity was created on Dec 09, 2015 and posted on Dec 09, 2015.
- Applicants must submit their applications by Sep 26, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)" (Funding Opportunity Number RFA-CA-16-002) is a National Institutes of Health (NIH) funding announcement from HHS (listed under HHS-NIH11) that supports exploratory projects aimed at pushing forward new and still-evolving technologies for cancer research. It is specifically designed for projects that move beyond early ideas and into advanced development and validation, meaning the core concept should already be shown to work at a proof-of-principle level. Applicants are expected to provide preliminary data that demonstrates the emerging technology or methodology can do something genuinely new or improved in the way it targets, probes, or measures molecular and cellular features that matter in cancer biology.
The main purpose of the FOA is technology advancement rather than discovery driven by an existing tool. The technology being proposed should meaningfully improve how researchers characterize cancer at the molecular and/or cellular level. In practical terms, the NIH is looking for tools, platforms, assays, or analytical methods that could sharpen what can be measured, detected, quantified, or interpreted in cancer systems. A strong application would explain how the proposed technology could accelerate research or expand what is possible in areas such as fundamental cancer biology, early detection and screening approaches, clinical diagnosis, treatment selection or monitoring, cancer control, epidemiology, and efforts aimed at understanding or reducing cancer health disparities. While the technologies may ultimately be broadly useful, they must stay clearly centered on enhancing molecular or cellular characterization in cancer rather than drifting into unrelated application areas.
A key boundary in this announcement is what it will not support. Projects that mainly apply established, widely used technologies to a new biological or clinical question are not considered responsive. In other words, novelty needs to be in the technology itself (or in a truly new technological capability), not simply in using a standard tool to study a different cancer type, patient group, or research problem. The FOA explicitly notes that applications focused on established technologies where the innovation is primarily the question being asked are not appropriate and will not be reviewed, so proposals need to make the case that the technology represents an emerging approach and that the work being funded is essential to mature, validate, and demonstrate that capability for cancer-relevant molecular or cellular analysis.
This opportunity uses the R33 grant mechanism, which generally aligns with later-stage exploratory and developmental work where feasibility has already been indicated and the next step is to strengthen performance, validate results, and demonstrate broader utility or readiness for use by the research community. The funding instrument is a discretionary grant under the activity category of education and health, and it is associated with CFDA numbers 93.394 (and also listed with an additional CFDA entry). The award ceiling is listed as $300,000, and the agency anticipated making about 10 awards under this announcement.
Eligibility is broad and includes many types of organizations that can carry out biomedical research and technology development. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other entities as described in the FOA's eligibility clarification text. This breadth signals that NIH is open to proposals from academic labs, research institutes, companies, and cross-sector partnerships, as long as the project goals match the technology-development focus.
The timeline information in the source data shows the opportunity was posted on December 9, 2015, with an original and current closing date of September 26, 2016. The intent of the program, based on the description, is to help promising early technologies cross a key development threshold so they can become reliable, validated tools that improve how cancer is measured and understood, and ultimately support better research and clinical outcomes through stronger molecular and cellular analysis capabilities.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-CA-16-002.
Which agency is offering this funding?
This is a National Institutes of Health (NIH) funding announcement from the U.S. Department of Health and Human Services (HHS), listed under HHS-NIH11.
What is the overall goal of this FOA?
The goal is to support exploratory projects that push forward new and still-evolving technologies for cancer research, specifically by advancing development and validation of emerging molecular and cellular analysis methods.
What stage of technology development is this FOA intended to support?
It is intended for projects that move beyond early ideas and into advanced development and validation. The core concept should already be demonstrated at a proof-of-principle level.
Are preliminary data required?
Yes. Applicants are expected to provide preliminary data demonstrating that the emerging technology or methodology can deliver a genuinely new or improved capability for targeting, probing, or measuring molecular and cellular features relevant to cancer biology.
What does NIH mean by "technology advancement" in this announcement?
The main purpose is to advance the technology itself rather than use an existing tool to make a biological discovery. The proposed work should mature, strengthen, validate, and demonstrate the emerging technological capability for cancer-relevant molecular or cellular analysis.
What kinds of technologies or approaches are in scope?
In-scope projects can include tools, platforms, assays, or analytical methods that meaningfully improve what researchers can measure, detect, quantify, or interpret in cancer systems at the molecular and/or cellular level.
What areas of cancer research could the proposed technologies support?
The FOA highlights potential impact areas such as fundamental cancer biology, early detection and screening approaches, clinical diagnosis, treatment selection or monitoring, cancer control, epidemiology, and research aimed at understanding or reducing cancer health disparities.
Does the proposed technology need to be centered on cancer?
Yes. Even if the technology could eventually be broadly useful, the project must remain clearly centered on enhancing molecular or cellular characterization in cancer and should not drift into unrelated application areas.
What kinds of projects are explicitly not responsive to this FOA?
Projects that mainly apply established, widely used technologies to a new biological or clinical question are not considered responsive. Novelty needs to be in the technology itself (or in a truly new technological capability), not simply in applying a standard tool to a different cancer type, patient group, or research question.
Will applications be reviewed if the innovation is mainly in the biological question rather than the technology?
No. The FOA notes that applications focused on established technologies where the innovation is primarily the question being asked are not appropriate and will not be reviewed.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R33 grant mechanism, which generally aligns with later-stage exploratory and developmental work where feasibility has already been indicated and the next step is to strengthen performance, validate results, and demonstrate broader utility or readiness for use by the research community.
What is the funding instrument and activity category?
The funding instrument is a discretionary grant, and the activity category is education and health.
What are the CFDA numbers associated with this opportunity?
The opportunity is associated with CFDA number 93.394 and is also listed with an additional CFDA entry.
What is the award ceiling for this announcement?
The award ceiling is listed as $300,000.
How many awards does NIH anticipate making?
NIH anticipated making about 10 awards under this announcement.
Who is eligible to apply?
Eligibility is broad and includes: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other entities as described in the FOA's eligibility clarification text.
Does this FOA allow applications from for-profit organizations and small businesses?
Yes. The eligibility list includes for-profit organizations other than small businesses as well as small businesses.
Can universities and other higher education institutions apply?
Yes. Both public/state-controlled institutions of higher education and private institutions of higher education are included as eligible applicants.
Are governmental entities eligible to apply?
Yes. Several types of governmental entities are included, such as state governments, county governments, city or township governments, special district governments, and independent school districts.
Are tribal governments or tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible applicants.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. The eligibility list includes nonprofits with and without 501(c)(3) status (other than institutions of higher education).
When was this opportunity posted?
The opportunity was posted on December 9, 2015.
What was the application closing date?
The original and current closing date shown is September 26, 2016.
What is the intended outcome of funding under this FOA?
The intent is to help promising early technologies cross a key development threshold so they become reliable, validated tools that improve how cancer is measured and understood, ultimately supporting better research and clinical outcomes through stronger molecular and cellular analysis capabilities.
Browse more opportunities from the same category: Education, Health
Next opportunity: Supporting the Implementation and Expansion of High Quality, Sustainable and Comprehensive HIV Prevention, Care and Treatment Programs in the Western Region and Turkana County of the Republic of Kenya under the President’s Emergency Plan for AIDS R
Previous opportunity: Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 16 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 16 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) Apply for RFA CA 16 004 Funding Number: RFA CA 16 004 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01) Apply for PAR 16 049 Funding Number: PAR 16 049 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Genomic Data Analysis Network: Processing Genomic Data Center (U24) Apply for RFA CA 15 018 Funding Number: RFA CA 15 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Apply for RFA NS 16 013 Funding Number: RFA NS 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01) Apply for PAR 16 051 Funding Number: PAR 16 051 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R01) Apply for PA 16 012 Funding Number: PA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) Apply for PA 16 035 Funding Number: PA 16 035 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R21) Apply for PAR 16 042 Funding Number: PAR 16 042 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (U10) Apply for PAR 16 056 Funding Number: PAR 16 056 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Innovative Questions in Symptom Science and Genomics (R01) Apply for PA 16 024 Funding Number: PA 16 024 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21) Apply for PAR 16 052 Funding Number: PAR 16 052 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $125,000 |
| Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01) Apply for RFA DA 16 011 Funding Number: RFA DA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Questions in Symptom Science and Genomics (R21) Apply for PA 16 023 Funding Number: PA 16 023 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01) Apply for PAR 16 059 Funding Number: PAR 16 059 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01) Apply for PA 16 030 Funding Number: PA 16 030 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Apply for RFA CA 16 001 Funding Number: RFA CA 16 001 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21) Apply for PA 16 029 Funding Number: PA 16 029 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01) Apply for RFA DA 16 014 Funding Number: RFA DA 16 014 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 16 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.